SU434943A1 - GASTROLE MEDICINE - Google Patents
GASTROLE MEDICINEInfo
- Publication number
- SU434943A1 SU434943A1 SU1251601A SU1251601A SU434943A1 SU 434943 A1 SU434943 A1 SU 434943A1 SU 1251601 A SU1251601 A SU 1251601A SU 1251601 A SU1251601 A SU 1251601A SU 434943 A1 SU434943 A1 SU 434943A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- gastrole
- medicine
- drug
- bile
- syndrome
- Prior art date
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
1one
Изобретение относитс к фармакологии.The invention relates to pharmacology.
Известна бычь желчь в составе препаратов , например аллохола, в качестве желчегонного средства.Known bovine bile in the composition of drugs, such as allohol, as a choleretic agent.
Целью изобретени вл етс создание лекарственного средства, сохран ющего в большей степени биологические свойства нативной желчи и потому вл ющегос более активным препаратом.The aim of the invention is to provide a drug that preserves the biological properties of native bile to a greater degree and therefore is a more active drug.
Исходным сырьем дл производства лекарственного средства вл етс бычь желчь.The feedstock for the manufacture of the drug is bovine bile.
Препарат примен ют при заболевани х, сопровождающихс гипохолией и ахолией: хроническом холецистите, холелитиазе, постхолецистэктомическом синдроме, хроническом эктероколите с гипомоторным синдромом и хирургических желчных свищах.The drug is used for diseases accompanied by hypocholia and acholias: chronic cholecystitis, cholelithiasis, postcholecystectomy syndrome, chronic ectocolitis with hypomotor syndrome and surgical biliary fistula.
Дозировка препарата 0,2-0,6 в день 3 раза в течение 1-3 мес цев (назначаетс индивидуально ). При необходимости курс лечеии повтор етс .The dosage of the drug is 0.2-0.6 per day, 3 times within 1-3 months (it is prescribed individually). If necessary, the course of treatment is repeated.
Лиофилизированна желчь представл ет собой порошок зеленовато-желтого цвета, горького вкуса, легко растворимый в воде, в 1%-ном содовом растворе.Lyophilized bile is a greenish-yellow powder, bitter in flavor, readily soluble in water, in a 1% soda solution.
Предмет изобретени Subject invention
Применение лиофилизированпой желчи (лиобила) в качестве желчегонного средства дл лечени хронического холецистита, холелитиаза , постхолецистэктомического синдрома, хронического энтероколита с гипомоторным синдромом и хирургических желчных свищей.The use of lyophilized bile (lyobil) as a choleretic agent for the treatment of chronic cholecystitis, cholelithiasis, postcholecystectomy syndrome, chronic enterocolitis with hypomotor syndrome, and surgical biliary fistula.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU1251601A SU434943A1 (en) | 1968-06-29 | 1968-06-29 | GASTROLE MEDICINE |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU1251601A SU434943A1 (en) | 1968-06-29 | 1968-06-29 | GASTROLE MEDICINE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU434943A1 true SU434943A1 (en) | 1974-07-05 |
Family
ID=20442806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU1251601A SU434943A1 (en) | 1968-06-29 | 1968-06-29 | GASTROLE MEDICINE |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU434943A1 (en) |
-
1968
- 1968-06-29 SU SU1251601A patent/SU434943A1/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Iannitti et al. | Effectiveness and safety of Arnica montana in post-surgical setting, pain and inflammation | |
| Braun et al. | Herbs and natural supplements, volume 2: An evidence-based guide | |
| JPH09512797A (en) | Cancer treatment and metastasis prevention | |
| Ho et al. | Bitter bottle gourd (Lagenaria siceraria) toxicity | |
| Basiri et al. | Topical effects of Artemisia absinthium ointment and liniment in comparison with piroxicam gel in patients with knee joint osteoarthritis: A randomized double-blind controlled trial | |
| EP0630644A4 (en) | Anti-microbial and interferon-inducing pharmaceutical compound. | |
| Biringanine et al. | Polysaccharides extracted from the leaves of Plantago palmata Hook. f. induce nitric oxide and tumor necrosis factor-α production by interferon-γ-activated macrophages | |
| SU434943A1 (en) | GASTROLE MEDICINE | |
| KR910700069A (en) | Treatment of Leukocyte Dysfunction Using GM-CSF | |
| CN106038534B (en) | Oridonin is preparing the purposes in anti-depression drug | |
| ES2879996T3 (en) | Chlorophyll composition | |
| Curtis et al. | Cephaloridine serum levels in patients on maintenance haemodialysis | |
| RU2008112667A (en) | METHODS FOR PERCUTRONARY CORONARY INTERVENTION | |
| JP2020100601A (en) | Nitric oxide synthase activator | |
| US2675340A (en) | Analgesic composition | |
| Biskind | The relation of nutritional deficiency to impaired libido and potency in the male | |
| Smith et al. | Clinical Trials, Potential Mechanisms, and Adverse Effects of Arnica as an Adjunct Medication for Pain Management. Medicines 2021, 8, 58 | |
| de Vries et al. | Clinical aspects of elapid bite | |
| RU2123350C1 (en) | Phytoconcentrate of curative-prophylactic effect for patients with diabetes mellitus | |
| Waugh | Systemic factors influencing wound healing | |
| RU2664441C1 (en) | Method for reducing the pro-oxidant effect of ultraviolet irradiation on the body | |
| KR20170116498A (en) | Pharmaceutical composition for arthritis | |
| SU1163862A1 (en) | Method of testing thyrotoxicosis cases | |
| SU449724A1 (en) | Mukaltin Expectorant | |
| Akuginova | Combination of antihelminthic drugs (phenasal and bithionole) for therapy of cestode inections. II. Investigation of the effectiveness of bithionole and of combination of bithionole with phenasal in treatment of taeniarhynchosis |